Unresolved Clinical Problems in Contemporary Coronary Interventional Cardiology

Narrative

Coronary interventional cardiology has reached a mature phase in which major clinical trials have resolved older questions and eliminated many earlier assumptions, but leaving new and important scientific questions unsettled. The period of rapid procedural expansion that followed the introduction of coronary angioplasty and intracoronary stents created a framework in which coronary stenosis served as the principal therapeutic target. Over the past two decades a sequence of large randomized trials forced reconsideration of that framework and revealed several conceptual uncertainties that continue to influence everyday decision making in the catheterization laboratory. These uncertainties concern the relationship between percutaneous coronary intervention and spontaneous myocardial infarction, the long-standing emphasis on ischemia as the central prognostic marker in stable coronary disease, the mechanism through which coronary bypass surgery achieves superior outcomes in selected anatomical settings, and the possibility that future treatment strategies may focus on plaques rather than stenoses. 

The first unresolved issue concerns the relationship between PCI and the later occurrence of spontaneous myocardial infarction. Data from the ISCHEMIA trial introduced a paradox that remains difficult to interpret. Early procedural myocardial infarction occurred more frequently among patients assigned to an invasive strategy that included PCI. During later follow up a lower incidence of spontaneous myocardial infarction appeared in the invasive group. Mortality remained similar between the two treatment strategies during the present period of observation. The biological explanation for this pattern remains uncertain. Most myocardial infarctions arise from plaques that produce little luminal obstruction before rupture, while PCI primarily treats lesions that limit coronary flow and produce ischemia during stress testing. A clear mechanistic link between relief of flow limitation and prevention of later plaque rupture therefore remains difficult to demonstrate. 

Some investigators suggest that the curves describing spontaneous myocardial infarction may separate further as follow up extends over a longer time horizon. Coronary atherosclerosis progresses slowly across decades rather than years, so a treatment that alters the natural course of disease might require ten or fifteen years before a large difference becomes visible. The continuing ISCHEMIA EXTEND follow up program aims to determine whether such divergence eventually appears. Until that information becomes available clinicians must interpret the existing evidence with caution because present data allow several possible explanations. 

A second issue concerns the historic emphasis on ischemia as the primary determinant of prognosis in stable coronary artery disease. For many years clinical practice assumed that a greater amount of ischemia signified higher risk and therefore justified revascularization. This assumption guided referral patterns, clinical guidelines, and daily decision making in catheterization laboratories throughout the world. Randomized trials later challenged this concept. The COURAGE trial demonstrated that PCI added to optimal medical therapy produced little improvement in survival or prevention of myocardial infarction among patients with stable symptoms. The ISCHEMIA trial reached a similar conclusion in patients with moderate or severe ischemia documented by stress imaging. 

These findings suggest a different biological model for coronary events. Stable obstructive lesions commonly produce angina through limitation of coronary flow during exertion, while plaques that rupture and trigger myocardial infarction frequently possess modest luminal narrowing before the acute event. In that framework plaque biology rather than stenosis severity determines the probability of infarction. The implication for interventional cardiology proves significant because treatment strategies based solely on angiographic obstruction may fail to address the lesions most likely to produce future events. Recognition of this distinction continues to influence discussion regarding the proper role of revascularization in stable disease. 

A third unresolved question concerns the consistent survival advantage observed with coronary artery bypass grafting among patients who possess complex multivessel disease. Trials such as SYNTAX, FAME 3, and STICH repeatedly demonstrated superior long-term outcomes for surgical revascularization in selected anatomical settings. Several explanations have been proposed. One possibility concerns the completeness of revascularization achieved by surgery because bypass grafts frequently supply blood beyond multiple obstructive segments within a single coronary artery. Greater completeness of revascularization could reduce ischemia across a larger myocardial territory. 

Another explanation focuses on a protective effect produced by bypass grafts that supply blood distal to long segments of diseased coronary artery. When a plaque ruptures in a proximal location within such a segment the graft may continue to deliver blood to the distal vessel and thereby preserve myocardial perfusion despite the acute event. PCI treats a discrete lesion yet leaves the remainder of the artery vulnerable to later rupture. Many cardiac surgeons believe that this distal protection explains the lower incidence of spontaneous myocardial infarction observed after bypass surgery. The hypothesis remains difficult to test directly yet provides a plausible physiological explanation for the differences seen in long term clinical trials. 

Beyond these specific questions lies a broader issue regarding the proper target for treatment. Current revascularization strategies focus on stenoses that restrict coronary flow. Rapid progress in coronary imaging now allows identification of plaques with biological features associated with future rupture. Optical coherence tomography can detect thin fibrous caps and macrophage infiltration. Near infrared spectroscopy identifies lipid rich plaque cores. Coronary computed tomography can characterize plaque composition within the arterial wall. These technologies raise the possibility that future therapy may address vulnerable plaques before rupture occurs even when the lesions produce little luminal obstruction. Such an approach would represent a substantial departure from the present stenosis centered paradigm. 

The historical environment in which earlier treatment strategies developed provides important perspective. During the 1980s and early 1990s medical therapy for atherosclerosis remained limited. Statins either had yet to appear or produced modest reductions in cholesterol levels. Antiplatelet therapy relied largely on aspirin alone. Angiotensin converting enzyme inhibitors saw limited use. Beta blockers remained underutilized in many patient populations. Smoking prevalence remained high while blood pressure control often proved inadequate. In that therapeutic landscape revascularization appeared particularly powerful because preventive pharmacology had yet to demonstrate its later strength. 

The landscape changed during the past fifteen years as preventive cardiology advanced through powerful lipid lowering therapy, modern antithrombotic strategies, neurohormonal blockade, and more aggressive management of hypertension and diabetes. High intensity statins combined with agents such as ezetimibe or PCSK9 inhibitors produce profound reductions in low density lipoprotein cholesterol. Contemporary antiplatelet therapy provides more reliable inhibition of platelet activation. Agents that influence the renin angiotensin aldosterone system improve vascular biology while modern diabetes therapies confer cardiovascular protection beyond glycemic control. These treatments influence plaque biology directly and reduce the probability of rupture. 

This transformation in medical therapy helps explain the declining event rates observed in recent clinical trials of coronary disease. When plaque rupture becomes less common through effective pharmacology the relative prognostic benefit of correcting luminal stenosis diminishes. Observers who watched event rates fall gradually over the past two decades therefore greeted the neutral results of trials such as ISCHEMIA and REVIVED BCIS2 with limited surprise. Coronary intervention continues to provide powerful relief of angina while the ability to prevent myocardial infarction increasingly depends on systemic treatment that stabilizes atherosclerotic plaque. 

The philosophy of clinical practice has shifted in response to these developments. For many years catheterization conferences revolved around the demonstration of ischemia and the implicit assumption that revascularization should follow. Contemporary discussions more often begin with a simpler question regarding symptom burden and quality of life. Coronary interventional cardiology therefore stands at a reflective moment in its history as physicians reconsider long standing assumptions while awaiting new discoveries that may redefine the therapeutic target itself.